|
1
|
Coburn SB, Bray F, Sherman ME and Trabert
B: International patterns and trends in ovarian cancer incidence,
overall and by histologic subtype. Int J Cancer. 140:2451–2460.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Barnett R: Ovarian cancer. Lancet.
387:12652016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hellstrom I and Hellstrom KE: SMRP and HE4
as biomarkers for ovarian carcinoma when used alone and in
combination with CA125 and/or each other. Adv Exp Med Biol.
622:15–21. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huang XM, Zhao YM, Pu Z-Y and Yu HY:
Clinical value of combined detection of serum CA125, HE4 and MMP-9
in early diagnosis of ovarian cancer. Labeled Immunoassays Clin
Med. 9:1029–1032. 2016.(In Chinese).
|
|
5
|
Zhang Y, Jiang L and Song L: Meta-analysis
of diagnostic value of serum carbohydrate antigen 199 in pancreatic
cancer. Minerva Med. 107:62–69. 2016.PubMed/NCBI
|
|
6
|
Zheng LE, Qu JY and He F: The diagnosis
and pathological value of combined detection of HE4 and CA125 for
patients with ovarian cancer. Open Med (Wars). 11:125–132.
2016.PubMed/NCBI
|
|
7
|
Ietimalar H, Koksal A, Chelik N, Kasap B,
Chukurova K and Iuldarum A: Evaluation of mammography and risk of
developing breast cancer in patients with ovarian or endometrial
cancer. Akush Ginekol (Sofiia). 48:23–30. 2009.(In Bulgarian).
PubMed/NCBI
|
|
8
|
Castellucci P, Perrone AM, Picchio M, Ghi
T, Farsad M, Nanni C, Messa C, Meriggiola MC, Pelusi G, Al-Nahhas
A, et al: Diagnostic accuracy of 18F-FDG PET/CT in
characterizing ovarian lesions and staging ovarian cancer:
correlation with transvaginal ultrasonography, computed tomography,
and histology. Nucl Med Commun. 28:589–595. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schirpenbach C, Seiler L, Maser-Gluth C,
Beuschlein F, Reincke M and Bidlingmaier M: Automated
chemiluminescence-immunoassay for aldosterone during dynamic
testing: Comparison to radioimmunoassays with and without
extraction steps. Clin Chem. 52:1749–1755. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wilailak S, Chan KK, Chen CA, Nam JH,
Ochiai K, Aw TC, Sabaratnam S, Hebbar S, Sickan J, Schodin BA, et
al: Distinguishing benign from malignant pelvic mass utilizing an
algorithm with HE4, menopausal status, and ultrasound findings. J
Gynecol Oncol. 26:46–53. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim CK, Park BK, Choi JY, Kim BG and Han
H: Detection of recurrent ovarian cancer at MRI: comparison with
integrated PET/CT. J Comput Assist Tomogr. 31:868–875. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ali AT: Fertility drugs and ovarian
cancer. Curr Cancer Drug Targets. 18:567–576. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moore RG, Jabre-Raughley M, Brown AK,
Robison KM, Miller MC, Allard WJ, Kurman RJ, Bast RC and Skates SJ:
Comparison of a novel multiple marker assay vs the Risk of
Malignancy Index for the prediction of epithelial ovarian cancer in
patients with a pelvic mass. Am J Obstet Gynecol. 203:e221–226.
2010. View Article : Google Scholar
|
|
14
|
Shen Y and Li L: Serum HE4 superior to
CA125 in predicting poorer surgical outcome of epithelial ovarian
cancer. Tumour Biol. 37:14765–14772. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fischerova D and Burgetova A: Imaging
techniques for the evaluation of ovarian cancer. Best Pract Res
Clin Obstet Gynaecol. 28:697–720. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guo J, Yu J, Song X and Mi H: Serum CA125,
CA199 and CEA combined detection for epithelial ovarian cancer
diagnosis: A meta-analysis. Open Med (Wars). 12:131–137.
2017.PubMed/NCBI
|
|
17
|
Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ,
Soletormos G, Torre GC, Tuxen MK and Zwirner M: CA125 in ovarian
cancer: European Group on Tumor Markers guidelines for clinical
use. Int J Gynecol Cancer. 15:679–691. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang Q, Wang CR, Yu JP, Ma Q and Xu WW:
The Establishment of an HE4-CLIA Method and the Combined Analysis
of HE4 and CA125 in Ovarian Cancer. J Clin Lab Anal. 30:709–718.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Iyer VR and Lee SI: MRI, CT, and PET/CT
for ovarian cancer detection and adnexal lesion characterization.
AJR Am J Roentgenol. 194:311–321. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang K, Wang L, Cheng S J and Leng W:
Diagnostic value of combined detection of serum CA125 and CA199 for
ovarian cancer. Chinese J Lab Diagnosis. 4:574–576. 2014.(In
Chinese).
|
|
21
|
Xu X-M and Jiang XS: Ultrasound combined
with CA125 and CEA in the diagnosis of ovarian cancer. Chinese J
Clin Oncol Rehab. 9:1059–1061. 2016.(In Chinese).
|
|
22
|
Rao A and Carter J: Ultrasound and ovarian
cancer screening: is there a future? J Minim Invasive Gynecol.
18:24–30. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schmidt S, Meuli RA, Achtari C and Prior
JO: Peritoneal carcinomatosis in primary ovarian cancer staging:
comparison between MDCT, MRI, and 18F-FDG PET/CT. Clin Nucl Med.
40:371–377. 2015. View Article : Google Scholar : PubMed/NCBI
|
